An Israeli biomed company, IceCure, has developed an FDA-approved process that kills benign tumor cells in the breast by freezing them. No surgery is required, and the procedure takes place in a doctor's office in 15 minutes or less, without pain, stitches, or scarring.
Benign breast tumors, or fibroadenomas, are very common--about 10% of women will get them. While they are not dangerous, they can be uncomfortable, so many women choose to have them removed. Before the development of IceCure's cryoablation technique, removing these tumors required surgery, which could deform the breasts.
Even more importantly, IceCure's cryoablation technology is being testing on malignant breast tumors, and early research has shown positive results: in a phase II trial completed in 2014, IceCure's technology was effective in destroying cancerous tumors less than 1 cm in diameter.
According to Dr. Rache Simmons, chief of breast surgery at New York Presbyterian/Cornell Weill Medical Center, “Compared to surgery, cryoablation is an effective non-surgical treatment for breast cancer in certain early stage patients.” Breast cancer kills nearly 50,000 women each year in the US alone.
Imagine what a gift this treatment could be to women throughout the world.